Eat your salmon: study shows fatty fish aids in cancer prevention
the ONA take:
Although recent studies have challenged the idea that eating more fatty fish is good for you, a new study published in the journal Nutrition and Cancer supports the theory that eating more fish can help to prevent cancer.
Investigators from an international team built on evidence that a regular low-dose of aspirin can decrease the risk for adenocarcinoma by decreasing the activity of cyclooxygenase-2 (COX-2), an enzyme that contributes to the progression of adenocarcinoma, by proposing that omega-3 fatty acids, which are found in fatty fish, can also inhibit COX-2. A high proportion of the cancers that originate in the breast, prostate, pancreas, colon, and GI tract are adenocarcinomas.
However, the authors of the study caution that it’s not just the amount of fish one consumes that can have an effect on the development of cancer, but also the kind of fish and how it is cooked. For example, in Italian subjects who consumed fish more than twice a week and cooked the fish in olive oil (rather than frying or preserving in salt) were found to be at a significantly lower risk for a variety of cancers.
It was also noted in this study that COX-2 is highly expressed in pre-malignant and early-stage adenocarcinomas, which is why the omega-3 fats are more effective in preventing cancer rather than as a therapeutic agent.
New study supports the theory that eating more fish can help to prevent cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|